Dinadayala Premkumar, Gleizal Géraldine, Guinamand Stéphanie, Bonifassi Patrick, Haensler Jean
Sanofi, R&D Department, Campus Mérieux, 69280, Marcy l'Etoile, France.
Biochem Biophys Rep. 2022 Dec 8;33:101405. doi: 10.1016/j.bbrep.2022.101405. eCollection 2023 Mar.
SPA09 is a polyacrylate-based clinical stage vaccine adjuvant that was found to exert a strong adjuvant effect on various vaccine antigens including recombinant cytomegalovirus glycoprotein B (CMV-gB). For the characterization of antigen-adjuvant interactions, which is a regulatory requirement and an important piece of information for the understanding of adjuvant mechanism of action, we developed a set of orthogonal techniques, comprising thermal analyses, biolayer interferometry and agarose gel migration assays. Here we apply these techniques to study the interaction between SPA09 and two recombinant proteins from the Sanofi new vaccine portfolio, CMV-gB and the chaperone protein, PrsA, that we used as model antigens. We believe that the techniques developed for this work could be useful to study the interactions between adjuvants and vaccine antigens in general and could be broadly applicable for the characterization of adjuvanted vaccine products.
SPA09是一种基于聚丙烯酸酯的临床阶段疫苗佐剂,已发现它对包括重组巨细胞病毒糖蛋白B(CMV-gB)在内的多种疫苗抗原具有强大的佐剂效应。为了表征抗原-佐剂相互作用,这是一项监管要求,也是理解佐剂作用机制的重要信息,我们开发了一套正交技术,包括热分析、生物层干涉测量法和琼脂糖凝胶迁移试验。在此,我们应用这些技术来研究SPA09与赛诺菲新疫苗组合中的两种重组蛋白CMV-gB和伴侣蛋白PrsA之间的相互作用,我们将这两种蛋白用作模型抗原。我们相信,为这项工作开发的技术总体上可用于研究佐剂与疫苗抗原之间的相互作用,并可广泛应用于佐剂疫苗产品的表征。